文献速递外周动脉疾病

西罗莫司药物涂层技术治疗股腘动脉病变的系统综述

Emerging Sirolimus-Based Drug-Coated Technologies for Femoropopliteal Disease: A Systematic Review.
PubMed 文献 · J Endovasc Ther · 2026-03-05

12个月一期通畅率为58.1%至94%,免于临床驱动的靶病变血运重建为74.3%至>95%,疗效与紫杉醇器械相当,但研究异质性大、随访较短且缺乏36个月以上数据。

要点

  • 西罗莫司涂层器械短期至中期疗效与安全性可接受,无特异性安全信号
  • 复杂病变(长病变、完全闭塞、严重钙化)中结果仍与紫杉醇器械相当
  • 现有证据以注册研究为主,随机对照试验有限,长期数据仍缺失

核心结论

  • 西罗莫司涂层器械是股腘动脉病变紫杉醇技术的有前景替代方案,短期至中期疗效令人鼓舞且安全性良好。
  • 当前证据受研究设计异质性、样本量小和随访相对较短限制,需更大规模随机试验确定长期安全性及临床地位。

研究设计与样本

  • 按PRISMA指南开展系统综述,检索PubMed、Scopus、Medline(自建库至2025年7月)及ClinicalTrials.gov和EU临床试验注册库。
  • 随机对照试验有限(SIROCCO I-II、SIRONA、ASCLEPIOS),多数数据来自前瞻性注册研究,6项研究采用独立核心实验室判定。

主要发现

  • 平均病变长度5.8至27.7 cm,完全闭塞比例最高达100%,严重钙化(PACSS 4级)最高达48%。
  • 12个月一期通畅率58.1%至94%,免于临床驱动的靶病变血运重建为74.3%至>95%。
  • 部分研究3年结果显示疗效持续,一期通畅率74.7%,免于临床驱动的靶病变血运重建92.9%。
  • 补救性支架置入率总体较低(0%至38%)。
  • 早期西罗莫司药物洗脱支架试验未优于裸支架,但新型器械(如NiTiDES)显示结局改善;未报告西罗莫司特异性不良安全信号,但缺乏36个月以上长期数据。

关键数值与推荐

  • 12个月一期通畅率58.1%至94%,免于临床驱动的靶病变血运重建74.3%至>95%。
  • 3年一期通畅率74.7%,免于临床驱动的靶病变血运重建92.9%(选自特定研究)。
  • 补救性支架置入率0%至38%;严重钙化PACSS 4级最高达48%。

临床怎么用

  • 在紫杉醇争议背景下,西罗莫司作为机制不同的细胞静止性替代方案,可谨慎整合进股腘动脉介入日常实践,尤其是复杂病变。
  • 新代西罗莫司器械显示结局优于早期药物洗脱支架,选择器械时需结合病变复杂度和现有证据。
  • 应告知患者长期(>36个月)安全性数据仍缺乏,并优先在有独立判定和长期随访的试验框架内使用。

局限性

  • 研究设计异质性强,随机对照试验数量有限,多数为前瞻性注册研究。
  • 样本量偏小,随访时间相对较短,缺乏36个月以上长期数据。
  • 各研究间病变复杂度和器械类型差异大,独立核心实验室判定的研究仅6项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To systematically review the current evidence on the use of sirolimus-coated endovascular devices for the treatment of femoropopliteal peripheral artery disease (PAD), focusing on efficacy, safety, and clinical feasibility. MATERIALS AND METHODS: A comprehensive systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Medline were searched from inception to July 2025, along with ClinicalTrials.gov and the EU Clinical Trials Register. Eligible studies included clinical trials in humans evaluating sirolimus-eluting balloons or sirolimus-eluting stents (DES) for femoropopliteal lesions. Data extracted included patient characteristics, lesion complexity, follow-up duration, primary patency (PP), freedom from clinically-driven target lesion revascularization (CD-TLR), and bailout stenting rates. RESULTS: Fifteen studies encompassing 2960 patients (2439 with femoropopliteal disease) were included. Randomized controlled trials were limited (SIROCCO I-II, SIRONA, ASCLEPIOS), with most data derived from prospective registries. Six studies incorporated independent core laboratory adjudication. Mean lesion length ranged from 5.8 to 27.7 cm, with total occlusions reported in up to 100% of cases and severe calcification (PACSS grade 4) in up to 48%. At 12 months, primary patency ranged from 58.1% to 94%, while freedom from CD-TLR varied between 74.3% and >95%. Three-year outcomes demonstrated sustained efficacy, with PP of 74.7% and CD-TLR freedom of 92.9% in selected studies. Bailout stenting was generally low (0%-38%). Early sirolimus DES trials did not demonstrate superiority over bare stents, but newer devices (eg, NiTiDES) showed improved outcomes. No sirolimus-specific adverse safety signals have been reported; however, long-term data beyond 36 months are missing. CONCLUSION: Sirolimus-coated devices offer a promising alternative to paclitaxel-based technologies for femoropopliteal PAD, with encouraging efficacy and a favorable short- to mid-term safety profile. Outcomes are comparable to those of paclitaxel devices, even in complex lesions. Nevertheless, current evidence is limited by heterogeneous study designs, small sample sizes, and relatively short follow-up. Larger randomized trials with independent adjudication and extended surveillance are required to define the long-term safety and clinical role of sirolimus in femoropopliteal interventions.Clinical ImpactThis systematic review consolidates the emerging clinical evidence on sirolimus-coated technologies for femoropopliteal disease, offering clinicians a structured appraisal of efficacy and safety across devices and lesion complexities. In the context of persistent debate surrounding paclitaxel, sirolimus represents a mechanistically distinct, cytostatic alternative with encouraging short- and mid-term outcomes and no current safety signal. For practicing interventionists, these findings support the cautious integration of sirolimus-coated balloons and newer-generation stents into daily practice, particularly in complex lesions. The innovation lies in controlled drug delivery platforms leveraging mTOR inhibition, potentially combining antiproliferative efficacy with improved vascular healing. Larger randomized trials will determine their definitive role in treatment algorithms.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Taneva GT, Muñoz Castellanos J. Emerging Sirolimus-Based Drug-Coated Technologies for Femoropopliteal Disease: A Systematic Review. J Endovasc Ther. 2026. PMID: 41784065. doi:10.1177/15266028261423157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。